CORONA Remedies Ltd.
•₹ 2,142.6-1.07%
2026-08-21
PROS
- Company has delivered good profit growth of 21.5% CAGR over last 5 years
- Company has a healthy return on capital (ROCE) of 30.1%
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.1%
- Latest quarter profit grew 29.5% YoY, showing strong momentum
- Company has delivered good sales growth of 19.5% CAGR over last 5 years
- Operating margins have improved to 20.6% from 15.0%
CONS
- Total debt has risen sharply - up 127.8% year on year
- Stock is trading at 12.8x its book value
- Rich enterprise valuation - EV/EBITDA of 31.6x
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1898.00 | 37.65 | 455393.78 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8525.00 | 77.37 | 226311.96 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 5013.00 | 87.43 | 190678.41 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1416.00 | 33.94 | 114392.01 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1105.00 | 24.42 | 110224.17 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2220.00 | 18.36 | 101506.15 | 0.81 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | MANKIND | 2391.00 | 48.34 | 98747.34 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 8. | DRREDDY | 1171.00 | 30.33 | 97740.54 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 9. | LAURUSLABS | 1807.00 | 89.30 | 97634.42 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1615.15 | 25.03 | 92932.16 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 414.30 | 136.32 | 67518.23 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | CORONA | 2123.85 | 65.26 | 12989.49 | 0.47 | 601.10 | 1201.08 | 4224.30 | 1118.99 | 31.74 | 22.05 |
Detailed Comparison with:
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 | |
| 247 | 228 | 239 | 288 | 283 | 259 | 291 | 345 | |
| Operating Profit | — | — | — | — | — | — | — | — |
| OPM % | — | — | — | — | — | — | — | — |
| Other Income | 2 | 1 | 1 | 2 | 2 | 2 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 | |
| Tax % | 25.07% | 22.94% | 27.79% | 23.80% | 25.08% | 25.26% | 17.28% | 25.20% |
| Net Profit | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| 7 | 7 | 5 | 1 | 9 | 7 | 7 | 1 | |
| Equity Capital | 61 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Equity Capital | 61 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Sep 2024
- 314
- 247
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2
- Interest
- 3
- Depreciation
- 9
- 57
- Tax %
- 25.07%
- Net Profit
- 43
- 7
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2024
- 298
- 228
- Operating Profit
- —
- OPM %
- —
- Other Income
- 1
- Interest
- 2
- Depreciation
- 10
- 58
- Tax %
- 22.94%
- Net Profit
- 45
- 7
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2025
- 294
- 239
- Operating Profit
- —
- OPM %
- —
- Other Income
- 1
- Interest
- 2
- Depreciation
- 10
- 43
- Tax %
- 27.79%
- Net Profit
- 31
- 5
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2025
- 347
- 288
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2
- Interest
- 2
- Depreciation
- 9
- 61
- Tax %
- 23.80%
- Net Profit
- 46
- 1
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2025
- 361
- 283
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2
- Interest
- 2
- Depreciation
- 9
- 70
- Tax %
- 25.08%
- Net Profit
- 52
- 9
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2025
- 342
- 259
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2
- Interest
- 2
- Depreciation
- 9
- 55
- Tax %
- 25.26%
- Net Profit
- 41
- 7
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2026
- 353
- 291
- Operating Profit
- —
- OPM %
- —
- Other Income
- 4
- Interest
- 1
- Depreciation
- 10
- 54
- Tax %
- 17.28%
- Net Profit
- 45
- 7
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2026
- 422
- 345
- Operating Profit
- —
- OPM %
- —
- Other Income
- 3
- Interest
- 3
- Depreciation
- 13
- 80
- Tax %
- 25.20%
- Net Profit
- 60
- 1
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 61
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | 1,479 | |
| 471 | 600 | 756 | 860 | 956 | 1,110 | 1,178 | |
| Operating Profit | 110 | 24 | 135 | 161 | 246 | 304 | — |
| OPM % | 19 | 4 | 15 | 16 | 21 | 22 | — |
| Other Income | 5 | 7 | 7 | 6 | 6 | 11 | 12 |
| Interest | 2 | 5 | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 16 | 20 | 20 | 28 | 37 | 38 | 42 |
| 92 | -1 | 111 | 118 | 198 | 240 | 260 | |
| Tax % | 24 | 50 | 23 | 24 | 25 | 23 | 24 |
| Net Profit | 70 | -0 | 85 | 90 | 149 | 185 | 199 |
| EPS | 11 | -0 | 15 | 15 | 24 | 30 | — |
| Dividend Payout % | 0 | -375 | 20 | 25 | 30 | 33 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 14 | -0 | 14 | 15 | 24 | 30 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 14 | -0 | 14 | 15 | 24 | 30 | — |
Mar 2021
- 576
- 471
- Operating Profit
- 110
- OPM %
- 19
- Other Income
- 5
- Interest
- 2
- Depreciation
- 16
- 92
- Tax %
- 24
- Net Profit
- 70
- EPS
- 11
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
Mar 2022
- 617
- 600
- Operating Profit
- 24
- OPM %
- 4
- Other Income
- 7
- Interest
- 5
- Depreciation
- 20
- -1
- Tax %
- 50
- Net Profit
- -0
- EPS
- -0
- Dividend Payout %
- -375
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- -0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- -0
Mar 2023
- 884
- 756
- Operating Profit
- 135
- OPM %
- 15
- Other Income
- 7
- Interest
- 4
- Depreciation
- 20
- 111
- Tax %
- 23
- Net Profit
- 85
- EPS
- 15
- Dividend Payout %
- 20
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
Mar 2024
- 1,014
- 860
- Operating Profit
- 161
- OPM %
- 16
- Other Income
- 6
- Interest
- 14
- Depreciation
- 28
- 118
- Tax %
- 24
- Net Profit
- 90
- EPS
- 15
- Dividend Payout %
- 25
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 15
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 15
Mar 2025
- 1,196
- 956
- Operating Profit
- 246
- OPM %
- 21
- Other Income
- 6
- Interest
- 11
- Depreciation
- 37
- 198
- Tax %
- 25
- Net Profit
- 149
- EPS
- 24
- Dividend Payout %
- 30
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 24
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 24
Mar 2026
- 1,403
- 1,110
- Operating Profit
- 304
- OPM %
- 22
- Other Income
- 11
- Interest
- 7
- Depreciation
- 38
- 240
- Tax %
- 23
- Net Profit
- 185
- EPS
- 30
- Dividend Payout %
- 33
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 30
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 30
TTM
- 1,479
- 1,178
- Operating Profit
- —
- OPM %
- —
- Other Income
- 12
- Interest
- 8
- Depreciation
- 42
- 260
- Tax %
- 24
- Net Profit
- 199
- EPS
- —
- Dividend Payout %
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 19%
- 3 Years:
- 17%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 21%
- 3 Years:
- 30%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 20%
- 3 Years:
- 25%
- Last Year:
- 27%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - |
| Equity Capital | 5 | 51 | 61 | 61 | 61 | 61 |
| 333 | 270 | 347 | 419 | 545 | 685 | |
| 5 | 2 | 2 | 31 | 11 | 127 | |
| Trade Payables | 72 | 85 | 94 | 114 | 144 | 147 |
| 170 | 146 | 158 | 249 | 257 | 278 | |
| Total Liabilities | 584 | 554 | 662 | 875 | 1,017 | 1,298 |
| ASSETS | - | - | - | - | - | - |
| 164 | 162 | 185 | 384 | 370 | 554 | |
| Capital Work in Progress | 0 | 14 | 65 | 121 | 186 | 143 |
| 37 | 14 | 31 | 25 | 25 | 25 | |
| 31 | 74 | 105 | 98 | 129 | 125 | |
| 0 | 0 | 0 | 100 | 118 | 146 | |
| Cash & Bank | 43 | 101 | 77 | 70 | 69 | 44 |
| 309 | 189 | 200 | 77 | 119 | 260 | |
| Total Assets | 584 | 554 | 662 | 875 | 1,017 | 1,298 |
| Total Debt | 50 | 34 | 2 | 134 | 63 | 143 |
| Net Working Capital | 191 | 136 | 154 | 66 | 99 | -13 |
| Contingent Liabilities | 0 | 0 | 0 | 0 | 0 | 1 |
| Book Value per Share | 727.08 | 62.86 | 66.70 | 78.51 | 99.04 | 121.97 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Total Debt | 50 | 34 | 2 | 134 | 63 | 143 |
| Net Working Capital | 191 | 136 | 154 | 66 | 99 | -13 |
| Contingent Liabilities | 0 | 0 | 0 | 0 | 0 | 1 |
| Book Value per Share | 727.08 | 62.86 | 66.70 | 78.51 | 99.04 | 121.97 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Mar 2021
- Equity Capital
- 5
- 333
- 5
- Trade Payables
- 72
- 170
- Total Liabilities
- 584
- 164
- Capital Work in Progress
- 0
- 37
- 31
- 0
- Cash & Bank
- 43
- 309
- Total Assets
- 584
- Total Debt
- 50
- Net Working Capital
- 191
- Contingent Liabilities
- 0
- Book Value per Share
- 727.08
- Face Value
- 10.00
- Total Debt
- 50
- Net Working Capital
- 191
- Contingent Liabilities
- 0
- Book Value per Share
- 727.08
- Face Value
- 10.00
Mar 2022
- Equity Capital
- 51
- 270
- 2
- Trade Payables
- 85
- 146
- Total Liabilities
- 554
- 162
- Capital Work in Progress
- 14
- 14
- 74
- 0
- Cash & Bank
- 101
- 189
- Total Assets
- 554
- Total Debt
- 34
- Net Working Capital
- 136
- Contingent Liabilities
- 0
- Book Value per Share
- 62.86
- Face Value
- 10.00
- Total Debt
- 34
- Net Working Capital
- 136
- Contingent Liabilities
- 0
- Book Value per Share
- 62.86
- Face Value
- 10.00
Mar 2023
- Equity Capital
- 61
- 347
- 2
- Trade Payables
- 94
- 158
- Total Liabilities
- 662
- 185
- Capital Work in Progress
- 65
- 31
- 105
- 0
- Cash & Bank
- 77
- 200
- Total Assets
- 662
- Total Debt
- 2
- Net Working Capital
- 154
- Contingent Liabilities
- 0
- Book Value per Share
- 66.70
- Face Value
- 10.00
- Total Debt
- 2
- Net Working Capital
- 154
- Contingent Liabilities
- 0
- Book Value per Share
- 66.70
- Face Value
- 10.00
Mar 2024
- Equity Capital
- 61
- 419
- 31
- Trade Payables
- 114
- 249
- Total Liabilities
- 875
- 384
- Capital Work in Progress
- 121
- 25
- 98
- 100
- Cash & Bank
- 70
- 77
- Total Assets
- 875
- Total Debt
- 134
- Net Working Capital
- 66
- Contingent Liabilities
- 0
- Book Value per Share
- 78.51
- Face Value
- 10.00
- Total Debt
- 134
- Net Working Capital
- 66
- Contingent Liabilities
- 0
- Book Value per Share
- 78.51
- Face Value
- 10.00
Mar 2025
- Equity Capital
- 61
- 545
- 11
- Trade Payables
- 144
- 257
- Total Liabilities
- 1,017
- 370
- Capital Work in Progress
- 186
- 25
- 129
- 118
- Cash & Bank
- 69
- 119
- Total Assets
- 1,017
- Total Debt
- 63
- Net Working Capital
- 99
- Contingent Liabilities
- 0
- Book Value per Share
- 99.04
- Face Value
- 10.00
- Total Debt
- 63
- Net Working Capital
- 99
- Contingent Liabilities
- 0
- Book Value per Share
- 99.04
- Face Value
- 10.00
Mar 2026
- Equity Capital
- 61
- 685
- 127
- Trade Payables
- 147
- 278
- Total Liabilities
- 1,298
- 554
- Capital Work in Progress
- 143
- 25
- 125
- 146
- Cash & Bank
- 44
- 260
- Total Assets
- 1,298
- Total Debt
- 143
- Net Working Capital
- -13
- Contingent Liabilities
- 1
- Book Value per Share
- 121.97
- Face Value
- 10.00
- Total Debt
- 143
- Net Working Capital
- -13
- Contingent Liabilities
- 1
- Book Value per Share
- 121.97
- Face Value
- 10.00
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 79 | 98 | 103 | 157 | 190 | 229 | |
| Cash from Investing | -102 | -66 | -50 | -267 | -84 | -256 |
| Cash from Financing | 0 | -30 | -45 | 99 | -107 | 25 |
| -23 | 2 | 8 | -11 | 0 | -1 | |
| Free Cash Flow | 79 | 66 | 10 | -126 | 106 | 51 |
| OCF / Net Profit | 1.13 | -244.26 | 1.21 | 1.73 | 1.28 | 1.24 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 | 106 |
| OCF / Net Profit | 1.13 | -244.26 | 1.21 | 1.73 | 1.28 | 1.24 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 | 106 |
Mar 2021
- 79
- Cash from Investing
- -102
- Cash from Financing
- 0
- -23
- Free Cash Flow
- 79
- OCF / Net Profit
- 1.13
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.13
- Cumulative 5-Year FCF
- 0
Mar 2022
- 98
- Cash from Investing
- -66
- Cash from Financing
- -30
- 2
- Free Cash Flow
- 66
- OCF / Net Profit
- -244.26
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- -244.26
- Cumulative 5-Year FCF
- 0
Mar 2023
- 103
- Cash from Investing
- -50
- Cash from Financing
- -45
- 8
- Free Cash Flow
- 10
- OCF / Net Profit
- 1.21
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.21
- Cumulative 5-Year FCF
- 0
Mar 2024
- 157
- Cash from Investing
- -267
- Cash from Financing
- 99
- -11
- Free Cash Flow
- -126
- OCF / Net Profit
- 1.73
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.73
- Cumulative 5-Year FCF
- 0
Mar 2025
- 190
- Cash from Investing
- -84
- Cash from Financing
- -107
- 0
- Free Cash Flow
- 106
- OCF / Net Profit
- 1.28
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.28
- Cumulative 5-Year FCF
- 0
Mar 2026
- 229
- Cash from Investing
- -256
- Cash from Financing
- 25
- -1
- Free Cash Flow
- 51
- OCF / Net Profit
- 1.24
- Cumulative 5-Year FCF
- 106
- OCF / Net Profit
- 1.24
- Cumulative 5-Year FCF
- 106
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| PER SHARE | - | - | - | - | - | - |
| EPS (₹) | 150.71 | -0.30 | 13.85 | 14.80 | 24.37 | 30.22 |
| Book Value (₹) | 727.08 | 62.86 | 66.70 | 78.51 | 99.04 | 121.97 |
| Dividend per Share (₹) | 0.00 | 1.14 | 2.77 | 3.70 | 7.31 | 10.00 |
| Cash EPS (₹) | 16.81 | 3.93 | 17.14 | 19.42 | 30.45 | 36.42 |
| PROFITABILITY | - | - | - | - | - | - |
| Operating Margin % | 18.11% | 3.76% | 14.96% | 14.92% | 19.71% | 20.56% |
| Net Margin % | 11.48% | -0.06% | 9.38% | 8.73% | 12.24% | 12.95% |
| ROE % | 20.73% | -0.12% | 23.24% | 20.38% | 27.45% | 27.35% |
| ROCE % | 24.36% | 1.11% | 30.04% | 25.94% | 32.55% | 31.74% |
| 11.97% | -0.07% | 13.93% | 11.77% | 15.76% | 15.97% | |
| EFFICIENCY | - | - | - | - | - | - |
| Debtor Days | 124 | 42 | 33 | 33 | 33 | 34 |
| Inventory Days | 18 | 42 | 36 | 36 | 34 | 33 |
| Payable Days | 182 | 211 | 155 | 168 | 199 | 203 |
| -40 | -127 | -86 | -99 | -132 | -137 | |
| FINANCIAL HEALTH | - | - | - | - | - | - |
| Debt to Equity (x) | 0.15x | 0.11x | 0.01x | 0.28x | 0.10x | 0.19x |
| Interest Coverage (x) | 47.03x | 0.83x | 26.93x | 9.21x | 19.69x | 35.45x |
| 2.00x | 1.70x | 1.74x | 1.24x | 1.30x | 0.97x | |
| GROWTH | - | - | - | - | - | - |
| Revenue Growth % | 0.00% | 0.00% | 43.21% | 14.75% | 17.93% | 17.28% |
| Operating Profit Growth % | 0.00% | 0.00% | 453.00% | 19.37% | 52.56% | 23.66% |
| Net Profit Growth % | 0.00% | 0.00% | 0.00% | 6.84% | 64.70% | 24.02% |
| 0.00% | 0.00% | 0.00% | 6.84% | 64.70% | 24.02% | |
| VALUATION | - | - | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 51.49x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 12.76x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.64% |
| 0.00x | 0.00x | 0.00x | 0.78x | 0.22x | 31.62x |
Mar 2021
- EPS (₹)
- 150.71
- Book Value (₹)
- 727.08
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 16.81
- Operating Margin %
- 18.11%
- Net Margin %
- 11.48%
- ROE %
- 20.73%
- ROCE %
- 24.36%
- 11.97%
- Debtor Days
- 124
- Inventory Days
- 18
- Payable Days
- 182
- -40
- Debt to Equity (x)
- 0.15x
- Interest Coverage (x)
- 47.03x
- 2.00x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2022
- EPS (₹)
- -0.30
- Book Value (₹)
- 62.86
- Dividend per Share (₹)
- 1.14
- Cash EPS (₹)
- 3.93
- Operating Margin %
- 3.76%
- Net Margin %
- -0.06%
- ROE %
- -0.12%
- ROCE %
- 1.11%
- -0.07%
- Debtor Days
- 42
- Inventory Days
- 42
- Payable Days
- 211
- -127
- Debt to Equity (x)
- 0.11x
- Interest Coverage (x)
- 0.83x
- 1.70x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2023
- EPS (₹)
- 13.85
- Book Value (₹)
- 66.70
- Dividend per Share (₹)
- 2.77
- Cash EPS (₹)
- 17.14
- Operating Margin %
- 14.96%
- Net Margin %
- 9.38%
- ROE %
- 23.24%
- ROCE %
- 30.04%
- 13.93%
- Debtor Days
- 33
- Inventory Days
- 36
- Payable Days
- 155
- -86
- Debt to Equity (x)
- 0.01x
- Interest Coverage (x)
- 26.93x
- 1.74x
- Revenue Growth %
- 43.21%
- Operating Profit Growth %
- 453.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2024
- EPS (₹)
- 14.80
- Book Value (₹)
- 78.51
- Dividend per Share (₹)
- 3.70
- Cash EPS (₹)
- 19.42
- Operating Margin %
- 14.92%
- Net Margin %
- 8.73%
- ROE %
- 20.38%
- ROCE %
- 25.94%
- 11.77%
- Debtor Days
- 33
- Inventory Days
- 36
- Payable Days
- 168
- -99
- Debt to Equity (x)
- 0.28x
- Interest Coverage (x)
- 9.21x
- 1.24x
- Revenue Growth %
- 14.75%
- Operating Profit Growth %
- 19.37%
- Net Profit Growth %
- 6.84%
- 6.84%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.78x
Mar 2025
- EPS (₹)
- 24.37
- Book Value (₹)
- 99.04
- Dividend per Share (₹)
- 7.31
- Cash EPS (₹)
- 30.45
- Operating Margin %
- 19.71%
- Net Margin %
- 12.24%
- ROE %
- 27.45%
- ROCE %
- 32.55%
- 15.76%
- Debtor Days
- 33
- Inventory Days
- 34
- Payable Days
- 199
- -132
- Debt to Equity (x)
- 0.10x
- Interest Coverage (x)
- 19.69x
- 1.30x
- Revenue Growth %
- 17.93%
- Operating Profit Growth %
- 52.56%
- Net Profit Growth %
- 64.70%
- 64.70%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.22x
Mar 2026
- EPS (₹)
- 30.22
- Book Value (₹)
- 121.97
- Dividend per Share (₹)
- 10.00
- Cash EPS (₹)
- 36.42
- Operating Margin %
- 20.56%
- Net Margin %
- 12.95%
- ROE %
- 27.35%
- ROCE %
- 31.74%
- 15.97%
- Debtor Days
- 34
- Inventory Days
- 33
- Payable Days
- 203
- -137
- Debt to Equity (x)
- 0.19x
- Interest Coverage (x)
- 35.45x
- 0.97x
- Revenue Growth %
- 17.28%
- Operating Profit Growth %
- 23.66%
- Net Profit Growth %
- 24.02%
- 24.02%
- P/E (x)
- 51.49x
- P/B (x)
- 12.76x
- Dividend Yield %
- 0.64%
- 31.62x
Documents
Announcements
- Analysts/Institutional Investor Meet/Con. Call Updates
2026-08-20 - CORONA Remedies Limited has informed the Exchange about Schedule of meet
- Analysts/Institutional Investor Meet/Con. Call Updates
2026-08-10 - CORONA Remedies Limited has informed the Exchange about Transcript
Annual Reports
Credit Ratings
Nothing filed yet.
Concalls
Aug 2026
Jul 2026
May 2026